Novel HIF2A mutations disrupt oxygen sensing, leading to polycythemia, paragangliomas, and somatostatinomas Blood, Mar 2013; 121: 2563 - 2566.
[anti-HA]
Regulation of the PI3-K/Akt Survival Pathway in the Rat Endometrium Biol Reprod, Mar 2013; 88: 79.
[Akt3]
RNA elements directing in vivo assembly of the 7SK/MePCE/Larp7 transcriptional regulatory snRNP Nucleic Acids Res., Mar 2013; 10.1093/nar/gkt159.
[LA]
Ruxolitinib as potential targeted therapy for patients with JAK2 rearrangements Haematologica, Mar 2013; 98: 404 - 408.
[JAK2]
Homo sapiens myosin, light chain 2, regulatory, cardiac, slow (MYL2)
Synonyms:
CMH10; MLC2
Immunogen
A synthetic peptide corresponding to residues in human Myosin Light Chain 2 was used as an immunogen.
Buffer
Store at -20 C. Buffer: 50 mM Tris-Glycine (pH 7.4), 0.15 M NaCl, 40% Glycerol, 0.01% sodium azide and 0.05% BSA. Stable for 12 months from date of receipt.
Myosin is a hexamer of 2 identical heavy chains and 2 pairs of light chains (1). The two pairs of light chains of muscle myosins are called essential light chains (ELC) and regulatory light chains (RLC). The light chains stabilize the long alpha helical neck of the myosin head (2). Myosin light chain-2 (MYL2), also known as the regulatory light chain of myosin, is an important protein involved in the regulation of myosin ATPase activity in smooth muscle (3). Calcium triggers the phosphorylation of MYL2 that in turn triggers contraction. The phosphorylation sites of MYL2 are mainly Serine 19 (monophosphorylation) and, in some conditions, both Threonine 18 and Serine 19 (diphosphorylation) (4). An increase in ventricular MYL2 is observed during myocardial hypertrophy in cardiac patients with valve stenosis (3).
Related Pathway
Focal Adhesion
* Shipping is in business days
* OriGene provides validated application data and protocol, with money back guarantee.
Western blot analysis on (A) fetal heart, (B) fetal skeletal muscle, (C) human heart, (D) mouse heart and (E) rat heart lysates using anti-Myosin Light Chain 2 RabMAb .
